Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces the appointments of Elizabeth Holt as Chief Business Officer (CBO) and Dr Mark ...

Past the halfway point the 2025 Colorado legislative session, the days are getting longer and the debates are growing more ...

The Government of Canada continues to make significant investments in Canada's biomanufacturing and life sciences sector to develop innovative solutions and long-term domestic biomanufacturing ...

Under the new leadership of chairman ... Roche entered into a collaboration agreement with Gilead Sciences, who had discovered oseltamivir, the primary antiviral drug used to combat avian ...

Gilead Sciences recently experienced a significant ... showcasing Gilead’s leadership in complex disease areas. In addition to these product and partnership milestones, Gilead's ongoing share ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $119.96. The business has a fifty day simple moving average of $100.99 and a 200 day simple moving average of $92.33.

In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market ...

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...

Gilead Sciences has declared a quarterly dividend to stockholders on record at the close of business on March 14, 2025. (Reuters) Gilead Sciences, with a market capitalization of $143.8 billion ...